ERBB3 and non-small cell lung carcinoma: GE-huMab-HER3 efficacy in vivo was assessed on a panel of primary NSCLC xenografts, where it caused >50% tumor growth inhibition in 10 out of 17 NSCLC cell lines and in some cases even resulted in complete tumor remission.